Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3973 |
Name | thyroid gland medullary carcinoma |
Definition | A thyroid gland carcinoma that has_material_basis_in parafollicular cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma thyroid gland medullary carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
RET C634W | Sorafenib | thyroid gland medullary carcinoma | sensitive | detail... |
RET M918T | Cabozantinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET mutant | Everolimus | thyroid gland medullary carcinoma | sensitive | detail... |
RET C620R | Everolimus | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET M918T | Everolimus | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET C634W | XMD15-44 | thyroid gland medullary carcinoma | sensitive | detail... |
RET C634W | ALW-II-41-27 | thyroid gland medullary carcinoma | sensitive | detail... |
RET C634W | HG-6-63-01 | thyroid gland medullary carcinoma | sensitive | detail... |
RET M918T | HG-6-63-01 | thyroid gland medullary carcinoma | sensitive | detail... |
RET M918T | XMD15-44 | thyroid gland medullary carcinoma | sensitive | detail... |
RET M918T | ALW-II-41-27 | thyroid gland medullary carcinoma | sensitive | detail... |
RET positive | Y078-DM4 | thyroid gland medullary carcinoma | sensitive | detail... |
RET M918T | AZD1480 | thyroid gland medullary carcinoma | sensitive | detail... |
RET mutant | Cabozantinib | thyroid gland medullary carcinoma | sensitive | detail... |
HRAS mutant | Cabozantinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET M918T | Sorafenib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET C634R | Sorafenib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET C634Y | Sorafenib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET C634F | Sorafenib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET C618R | Sorafenib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
ATM L804fs ATM S978fs RET M918T | Everolimus + Vandetanib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET C634W | RXDX-105 | thyroid gland medullary carcinoma | sensitive | detail... |
RET C634W | Pralsetinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET C609X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET C611X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET C618X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET C620X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET C630X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET C634X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET A883X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET M918X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET V804M RET E805K | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET V804M RET Y806C | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET V804M RET S904C | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET E768X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET L790X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET Y791X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET V804X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET S891X | N/A | thyroid gland medullary carcinoma | not applicable | detail... |
RET L629P RET D631_R635delinsG RET V637R | Pralsetinib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET M918T | Pralsetinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET mutant | Selpercatinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET V804M | Selpercatinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET M918T | Selpercatinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET C634W | Selpercatinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET V804M RET M918T | Everolimus + Vandetanib | thyroid gland medullary carcinoma | resistant | detail... |
RET V804M RET M918T | Selpercatinib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET fusion | Selpercatinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET V804L | Selpercatinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET V804M RET G810S RET L881V RET M918T | Selpercatinib | thyroid gland medullary carcinoma | predicted - resistant | detail... |
RET mutant | Pralsetinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET C634X | Pralsetinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET V804X | Pralsetinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET D378_G385delinsE | Selpercatinib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET fusion | Pralsetinib | thyroid gland medullary carcinoma | sensitive | detail... |
RET C634W | Pz-1 | thyroid gland medullary carcinoma | sensitive | detail... |
RET M918T | Pz-1 | thyroid gland medullary carcinoma | sensitive | detail... |
RET C634W | SYHA1815 | thyroid gland medullary carcinoma | sensitive | detail... |
NRAS mutant | Cabozantinib | thyroid gland medullary carcinoma | sensitive | detail... |
ALK rearrange | Crizotinib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET E632_L633del | Selpercatinib | thyroid gland medullary carcinoma | conflicting | detail... |
RET D631_L633delinsS | Selpercatinib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET V591_G607del RET L1016S | Pralsetinib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
MLH1 negative | Pembrolizumab | thyroid gland medullary carcinoma | sensitive | detail... |
MSH6 negative | Pembrolizumab | thyroid gland medullary carcinoma | sensitive | detail... |
RET D898_E901del | Vandetanib | thyroid gland medullary carcinoma | predicted - resistant | detail... |
RET D898_E901del | Selpercatinib | thyroid gland medullary carcinoma | predicted - sensitive | detail... |
RET C634W | Vepafestinib | thyroid gland medullary carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01396408 | Phase II | Temsirolimus Sunitinib | A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours | Active, not recruiting | CAN | 0 |
NCT01838642 | Phase II | Ponatinib | Ponatinib for Advanced Medullary Thyroid Cancer | Terminated | USA | 0 |
NCT01896479 | FDA approved | Cabozantinib | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer (EXAMINER) | Active, not recruiting | ITA | FRA | ESP | CAN | AUS | 9 |
NCT02657551 | Phase II | Regorafenib | A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT02831179 | Phase I | Capecitabine + Temozolomide + Veliparib | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | Withdrawn | 0 | |
NCT02867592 | Phase II | Cabozantinib | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Active, not recruiting | USA | 0 |
NCT02936323 | Phase Ib/II | PEN-221 | PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | Completed | USA | GBR | 0 |
NCT03037385 | Phase Ib/II | Pralsetinib | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | BEL | 6 |
NCT03072160 | Phase II | Pembrolizumab | Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer | Completed | USA | 0 |
NCT03157128 | Phase Ib/II | Selpercatinib | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (LIBRETTO-001) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 7 |
NCT03753919 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) | Active, not recruiting | ESP | 0 |
NCT03780517 | Phase I | DS-5010 | Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors | Completed | USA | FRA | ESP | BEL | 3 |
NCT03838692 | Phase II | Ponatinib | Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer | Withdrawn | 0 | |
NCT04106843 | Phase II | lutetium Lu 177 dotatate | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers | Withdrawn | USA | 0 |
NCT04211337 | Phase III | Vandetanib Cabozantinib Selpercatinib | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 12 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Recruiting | USA | 0 |
NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) | Active, not recruiting | USA | GBR | CAN | 1 |
NCT04759911 | Phase II | Selpercatinib | Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer | Recruiting | USA | 0 |
NCT04760288 | Phase III | Cabozantinib Pralsetinib Vandetanib | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). (AcceleRET-MTC) | Recruiting | ESP | 0 |
NCT05241834 | Phase I | LOXO-260 | A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment | Recruiting | USA | 0 |